Xylem Inc.
XYL
$107.85
+0.57%
Xylem Inc. is a global water technology company that designs and manufactures equipment and solutions for the transport, treatment, testing, and efficient use of water across utility, industrial, commercial, and residential end markets, operating through three reporting segments: Water Infrastructure, Measurement and Control Solutions, and Applied Water. Spun off from ITT in 2011 and headquartered in Rye Brook, New York, Xylem has grown into one of the largest pure-play water technology platforms in the world, with roughly $9 billion in annual revenue, operations in over 150 countries, and a workforce of approximately 22,000 employees. The current investor narrative is dominated by a stark disconnect between the company's steady operational execution and its sharply deteriorating share price, which has fallen roughly 24% over the past year even as quarterly revenue grew 2.7% year over year and management continues to expand margins. Bulls point to resilient demand for water infrastructure, a healthy balance sheet, and a consensus analyst target implying substantial upside, while bears focus on the stock's severe underperformance versus the S&P 500, soft top-line growth, and questions about whether end-market conditions are weakening. The debate now centers on whether this is a temporary sentiment-driven dislocation in a high-quality industrial franchise or the early stages of a more durable earnings deceleration.…
XYL
Xylem Inc.
$107.85
Investment Opinion: Should I buy XYL Today?
Rating: Hold. Xylem is a high-quality water technology franchise trading at a significant discount to its historical valuation and analyst targets, but the near-term technical and fundamental momentum is negative. The consensus analyst rating is 'buy' with an average target of $153.88 (43.1% upside), yet the stock is down 24.35% over one year and sits just 4.6% above its 52-week low, suggesting the market is pricing in risks that analysts have not fully incorporated.\n\nThe supporting evidence for a Hold is balanced: the forward PE of 17.22x is reasonable for a company with stable gross margins (37.79% in Q1 2026) and a fortress balance sheet (debt-to-equity of 0.18), and the PB ratio of 2.89x is near the low end of its five-year range (2.64x–7.21x). However, revenue growth has decelerated to 2.71% YoY, Q1 free cash flow was only $18 million, and the PEG ratio of 4.89 signals the stock is not cheap on a growth-adjusted basis. The dividend yield of 1.18% is above the stock's historical average, but the payout ratio of 40.86% and weak Q1 cash flow raise questions about dividend sustainability if cash conversion does not improve.\n\nThe biggest risks that could invalidate a bullish thesis are a continued deceleration in revenue growth below 2%, further margin compression, and a breakdown below the 52-week low of $105.29. This Hold would upgrade to Buy if Q2 2026 revenue growth reaccelerates above 5% and free cash flow normalizes above $200 million, or if the stock forms a technical base above $105 with improving relative strength. It would downgrade to Sell if revenue growth turns negative, gross margins fall below 37%, or the stock breaks below $105 on high volume. Relative to its history and peers, Xylem appears undervalued on a forward PE basis but fairly valued to slightly expensive on trailing metrics; the market is pricing in a successful earnings recovery that has yet to materialize.
Sign up to view all
XYL 12-Month Price Forecast
Xylem presents a classic value-versus-momentum dilemma: the stock is deeply out of favor, trading near its 52-week low with negative relative strength, yet the forward valuation of 17.22x and the 43.1% upside to analyst targets suggest significant undervaluation if earnings estimates are met. The key uncertainty is whether the revenue deceleration to 2.71% is a temporary pause or the start of a more durable slowdown; the wide analyst target range of $129–$180 reflects this disagreement. The strong balance sheet (D/E 0.18) and stable gross margins provide downside protection, but the weak Q1 free cash flow of $18 million and the elevated PEG ratio of 4.89 limit the near-term upside. I would upgrade to bullish if Q2 2026 revenue growth exceeds 5% and free cash flow normalizes above $200 million, and downgrade to bearish if revenue growth turns negative or the stock breaks below $105 on high volume.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Xylem Inc.'s 12-month outlook, with a consensus price target around $153.88 and implied upside of +42.7% versus the current price.
Average Target
$153.88
0 analysts
Implied Upside
+42.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$129 - $180
Analyst target range
Xylem is covered by 16 analysts with a consensus recommendation of "buy" and a recommendation mean of 1.86 (where 1.0 is a strong buy and 5.0 is a strong sell), indicating a bullish consensus despite the stock's poor price performance. The average target price of $153.88 implies 43.1% upside from the current price of $107.56, a substantial gap that reflects either significant undervaluation or stale analyst estimates that have not yet been revised downward to reflect deteriorating sentiment. The consensus skews bullish, with the buy rating and high target suggesting that the analyst community views the selloff as overdone relative to fundamental value. However, the persistence of such a wide gap between price and target — the stock is trading 30.1% below the average target — raises the question of whether analysts are lagging the market's reassessment or whether the market is mispricing the stock. The target range spans from a low of $129.00 to a high of $180.00, a spread of $51.00 or 39.5% of the low target, which signals meaningful disagreement among analysts about the company's prospects. The low target of $129.00 still implies 19.9% upside from current levels, suggesting that even the most conservative analyst sees the stock as undervalued — a notable signal given the stock is near its 52-week low. The high target of $180.00 implies 67.3% upside and would require a full recovery to near the 52-week high of $154.27 and beyond, pricing in multiple expansion, accelerating revenue growth, and successful execution on margin initiatives. The wide spread indicates high uncertainty, likely driven by divergent views on end-market demand, the trajectory of the industrial cycle, and the company's ability to accelerate growth from the current low-single-digit rate. Institutional ratings show a mix of actions: Jefferies upgraded to Buy from Hold on June 25, 2026, while UBS downgraded to Neutral from Buy on April 21, 2026, and then maintained Neutral on April 29 — a pattern of divergent views that reinforces the lack of consensus on near-term direction. The estimated EPS average of $7.78 for the forward year, with a range of $7.61 to $7.99, shows relatively tight earnings estimates despite the wide price target range, suggesting the disagreement is more about the appropriate multiple than about earnings power. The key takeaway is that analyst sentiment remains constructive, but the market is voting otherwise; until the price action confirms the analysts' thesis, the risk of further downside remains.
Drowning in data?
Find the real signal!
Bulls vs Bears: XYL Investment Factors
The bear case currently has stronger near-term evidence: the stock is in a confirmed downtrend, down 24.35% over one year with deeply negative relative strength (-39.36% vs. SPY), revenue growth has decelerated to 2.71%, and Q1 free cash flow collapsed to $18 million. However, the bull case rests on a compelling valuation disconnect—forward PE of 17.22x, PB of 2.89x near multi-year lows, and a 43.1% upside to the average analyst target of $153.88—supported by a fortress balance sheet (D/E 0.18) and still-growing earnings (+9.5% YoY). The single most important tension is whether the revenue deceleration is a temporary pause or the start of a durable earnings downturn; if Q2 2026 revenue growth reaccelerates above 5% and free cash flow normalizes, the stock could re-rate sharply, but if growth stalls below 2% and margins compress, the forward estimates of $7.78 EPS will prove too optimistic and the stock could break its 52-week low.
Bullish
- Deep analyst discount to price: The average analyst target of $153.88 implies 43.1% upside from $107.56, and even the lowest target of $129.00 implies 19.9% upside. With 16 analysts and a consensus recommendation of 'buy' (mean 1.86), the selloff appears disconnected from fundamental expectations.
- Fortress balance sheet: Debt-to-equity of just 0.18 and a current ratio of 1.625 provide substantial financial flexibility. This low leverage supports continued buybacks and dividends even through a cyclical downturn, reducing solvency risk.
- Earnings still growing: Q1 2026 net income of $185 million rose 9.5% from $169 million in Q1 2025, even as revenue growth decelerated to 2.71%. This demonstrates operating leverage and cost discipline amid softer top-line trends.
- Valuation near historical lows: The PB ratio of 2.89x is well below the five-year historical range of 2.64x–7.21x, and the forward PE of 17.22x is in the lower quartile of the historical PE band. The market is pricing Xylem at a significant discount to its own history.
Bearish
- Severe relative underperformance: XYL is down 24.35% over one year versus the S&P 500's +15.01%, a relative strength gap of -39.36%. The stock is also down 21.55% YTD versus the S&P's +11.70%, indicating active abandonment by investors.
- Decelerating revenue growth: Q1 2026 revenue growth slowed to 2.71% YoY from 6.3% in Q4 2025, 7.8% in Q3 2025, and 6.1% in Q2 2025. This deceleration undermines the premium multiple narrative and raises questions about end-market demand.
- Cash flow deterioration: Q1 2026 free cash flow was just $18 million, down sharply from $460 million in Q4 2025 and $281 million in Q3 2025, driven by a $216 million working capital outflow. Dividends and buybacks were effectively funded from the balance sheet.
- Technical breakdown risk: At $107.56, the stock sits just 4.6% above its 52-week low of $105.29 and 30.3% below its 52-week high. A decisive break below $105.29 could trigger momentum-driven selling and open the door to new lows.
XYL Technical Analysis
Xylem is in a sustained downtrend, with the stock down 24.35% over the past year and 21.55% year to date, a stark contrast to the S&P 500's +15.01% one-year and +11.70% YTD gains. At $107.56, the shares are trading at just 4.6% above their 52-week low of $105.29 and 30.3% below their 52-week high of $154.27, placing the stock at roughly 4.6% of its 52-week range — a positioning that signals persistent selling pressure rather than a value opportunity until a base forms. The maximum drawdown of -30.9% confirms the severity of the decline, and with the stock hovering near the bottom of its annual range, the burden of proof rests on buyers to demonstrate that support will hold. Recent momentum remains negative but is decelerating: the 1-month change of -7.44% is worse than the 3-month change of -3.46% and the 6-month change of -10.69%, indicating the selloff has re-accelerated in recent weeks rather than stabilized. Relative strength versus SPY is deeply negative across every window — -6.48% over 1 month, -5.46% over 3 months, -28.13% over 6 months, and -39.36% over 1 year — showing that Xylem is not merely falling but is being actively abandoned relative to the market. The most recent price action is telling: after rallying to $125.30 on July 16, the stock slid to $105.69 by September 4 and has since chopped sideways in the $106-$108 range, a pattern that suggests near-term stabilization but no confirmed reversal. The 52-week low at $105.29 is the critical support level; a decisive breakdown below it would likely trigger momentum-driven selling and open the door to new lows, while the 52-week high at $154.27 represents the distant resistance that would need to be reclaimed to signal a genuine trend change. With a beta of 1.0, Xylem moves roughly in line with the broader market, meaning the underperformance is company- and sector-specific rather than a function of elevated volatility; the short ratio of 4.98 days indicates a moderate short base that could amplify a squeeze if positive catalysts emerge. Volume of 4.39 million shares suggests adequate liquidity for institutional positioning, but the lack of a volume-backed reversal near the lows leaves the technical picture firmly bearish until proven otherwise.
Beta
1.00
1.00x market volatility
Max Drawdown
-30.9%
Largest decline past year
52-Week Range
$105-$154
Price range past year
Annual Return
-24.9%
Cumulative gain past year
| Period | XYL Return | S&P 500 |
|---|---|---|
| 1m | -4.9% | +1.0% |
| 3m | -3.7% | +5.5% |
| 6m | -9.7% | +19.9% |
| 1y | -24.9% | +16.0% |
| ytd | -21.3% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
XYL Fundamental Analysis
Xylem's revenue trajectory is growing but at a modest pace, with Q1 2026 revenue of $2.125 billion representing 2.71% year-over-year growth from $2.069 billion in Q1 2025. The multi-quarter trend shows sequential softness: revenue declined from $2.397 billion in Q4 2025 to $2.268 billion in Q3 2025 and $2.301 billion in Q2 2025, reflecting normal seasonality but also suggesting limited top-line acceleration. On a year-over-year basis, growth has been consistently in the low single digits — Q4 2025 revenue of $2.397 billion versus $2.256 billion in Q4 2024 (+6.3%), Q3 2025's $2.268 billion versus $2.103 billion (+7.8%), and Q2 2025's $2.301 billion versus $2.169 billion (+6.1%) — but the most recent quarter's 2.71% growth marks a deceleration from those mid-single-digit rates. Segment data shows Water Infrastructure as the largest contributor at $2.055 billion, followed by Measurement and Control Solutions at $1.596 billion and Applied Water at $1.414 billion, with the utility-facing infrastructure business likely providing the most stable demand while industrial-exposed segments face cyclical headwinds. The decelerating growth profile is the central fundamental concern for investors, as it undermines the premium multiple the stock has historically commanded and raises questions about whether the water infrastructure supercycle narrative is translating into near-term financial results. Profitability remains solid, with Q1 2026 net income of $185 million and a net margin of 8.71%, though this was down from Q4 2025's $335 million and 13.98% net margin. Gross margin in Q1 2026 was 37.79%, consistent with the 38.88% in Q4 2025 and 38.93% in Q3 2025, indicating stable but not expanding gross profitability; the trailing twelve-month gross margin of 38.46% and operating margin of 13.54% reflect a business with decent but not exceptional profitability for an industrial machinery company. The quarterly net income pattern shows meaningful volatility — $185 million in Q1 2026, $335 million in Q4 2025, $227 million in Q3 2025, $226 million in Q2 2025, and $169 million in Q1 2025 — with the Q1 2026 result representing a 9.5% increase over Q1 2025's $169 million, a positive sign that earnings are still growing even as revenue growth slows. However, the net margin compression from 13.98% in Q4 2025 to 8.71% in Q1 2026, while partly seasonal, warrants monitoring to determine whether it reflects temporary cost pressures or a more structural margin challenge. The balance sheet is a clear strength: debt-to-equity of just 0.18 is exceptionally low for an industrial company, the current ratio of 1.625 indicates solid short-term liquidity, and ROE of 8.34% and ROA of 5.11% reflect a conservatively financed business. Free cash flow on a trailing twelve-month basis is $966 million, which against a market cap of $33.1 billion yields an FCF yield of approximately 2.9% — modest but supported by the low leverage. However, Q1 2026 free cash flow was only $18 million, a sharp decline from $460 million in Q4 2025 and $281 million in Q3 2025, driven by a $216 million working capital outflow and $563 million in stock repurchases that consumed cash. The company paid $106 million in dividends in Q1 2026 while generating just $108 million in operating cash flow, meaning the dividend and buyback were effectively funded from the balance sheet rather than organic cash generation in the quarter — a dynamic that is sustainable given the strong balance sheet but not indefinitely. With a payout ratio of 40.86% and dividend yield of 1.18%, the dividend appears well-covered on a trailing basis, but the Q1 cash flow weakness bears watching.
Quarterly Revenue
$2.1B
2026-03
Revenue YoY Growth
+2.7%
YoY Comparison
Gross Margin
37.8%
Latest Quarter
Free Cash Flow
$966000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is XYL Overvalued?
Because Xylem is profitable — Q1 2026 net income of $185 million and trailing EPS of $0.0289 on a reported basis (though the quarterly EPS of $0.79 and consensus forward EPS of $7.78 are more representative) — the PE ratio is the appropriate primary valuation metric. The trailing PE of 34.65x compares to a forward PE of 17.22x, a dramatic 50.3% compression that implies the market expects earnings to roughly double, consistent with the consensus forward EPS estimate of $7.78 versus the trailing figure. This wide gap between trailing and forward multiples is a double-edged sword: it signals strong expected earnings growth, but it also means the stock's valuation is highly dependent on execution against those optimistic estimates, leaving little room for disappointment. The PEG ratio of 4.89 is elevated, suggesting that even after accounting for growth, the stock is not cheap on a growth-adjusted basis. Relative to the broader industrial machinery sector, Xylem's forward PE of 17.22x appears reasonable, but the trailing PE of 34.65x and PS ratio of 3.67x suggest the market has historically awarded the company a premium multiple. The EV/EBITDA of 18.90x and EV/Sales of 2.98x are moderate for a high-quality water technology franchise but not inexpensive in absolute terms. The PB ratio of 2.89x is notably below the company's historical levels — historical PB ratios ranged from 2.64x to 7.21x over the past five years — indicating that the market is now valuing Xylem's equity at a significant discount to its own history. The dividend yield of 1.18% is above the stock's historical average (historical yields ranged from 0.24% to 0.39% in the data provided, though those appear to be quarterly figures), reflecting the share price decline rather than a dividend increase. Comparing the current valuation to Xylem's own historical range, the stock is trading near the low end of its five-year PE band: historical quarterly PE ratios ranged from 21.65x to 327.93x, with the current 34.65x sitting in the lower quartile of that range. The PS ratio of 3.67x is also well below the historical range of 10.33x to 17.62x, though the historical data appears to use a different share count or methodology, making direct comparison imperfect. The forward PE of 17.22x, if achieved, would represent a valuation more in line with a mature industrial company than a premium growth franchise, suggesting that either the market is pricing in a significant earnings recovery or the stock has been de-rated to a level that may prove attractive if growth stabilizes. The key risk is that the forward estimates prove too optimistic; if earnings disappoint, the forward PE would rise toward the trailing level, implying further downside.
PE
34.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 22x~63x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
18.9x
Enterprise Value Multiple
Investment Risk Disclosure
Xylem's financial risks center on its decelerating revenue growth and deteriorating cash conversion. Q1 2026 revenue grew just 2.71% YoY, down from 6.3% in Q4 2025, while Q1 free cash flow fell to $18 million from $460 million in the prior quarter due to a $216 million working capital outflow. The company paid $106 million in dividends and repurchased $563 million in stock during Q1, effectively funding shareholder returns from the balance sheet rather than organic cash generation. With a payout ratio of 40.86% and net margin compressing to 8.71% in Q1 2026 from 13.98% in Q4 2025, the dividend and buyback are sustainable only if cash flow normalizes in subsequent quarters. Additionally, the forward PE of 17.22x versus trailing PE of 34.65x implies the market expects earnings to roughly double, leaving little room for execution missteps.\n\nMarket and competitive risks are amplified by Xylem's premium valuation history and its exposure to industrial and utility capex cycles. The stock trades at a PS ratio of 3.67x and EV/EBITDA of 18.90x, which, while below historical peaks, still embeds expectations of a growth recovery. With a beta of 1.0, Xylem moves in line with the broader market, but its -39.36% one-year relative strength versus the S&P 500 shows company-specific de-rating rather than macro-driven weakness. The wide analyst target range of $129 to $180 (a 39.5% spread) signals high uncertainty about end-market demand, particularly in the industrial-exposed Applied Water and Measurement & Control segments. Recent analyst actions have been mixed—Jefferies upgraded to Buy in June 2026 while UBS downgraded to Neutral in April 2026—reflecting divergent views on the durability of the water infrastructure supercycle.\n\nThe worst-case scenario would involve a continued deceleration in revenue growth below 2%, further margin compression, and a breakdown below the 52-week low of $105.29. This could occur if industrial capex weakens, utility spending delays materialize, and the company fails to convert its backlog into revenue. In such a scenario, the stock could retest its 52-week low of $105.29 (a 2.1% decline from current levels) and potentially fall toward the analyst low target of $129.00—though that target is above the current price, suggesting the true downside may be lower if estimates are revised down. A more severe outcome, such as a recession-driven earnings miss, could push the stock to $90–$95, representing a 12–16% decline from $107.56. The maximum drawdown over the past year was already -30.9%, and a similar move from current levels would take the stock to roughly $74, though that would require a significant deterioration in fundamentals beyond current expectations.
FAQ
The most severe risk is a continued deceleration in revenue growth, which fell to 2.71% YoY in Q1 2026 from 6.3% in Q4 2025; if growth turns negative, the forward EPS estimates of $7.78 will be at risk. Second, cash flow deterioration is a concern: Q1 2026 free cash flow was just $18 million, down from $460 million in Q4 2025, and the company funded $106 million in dividends and $563 million in buybacks partly from the balance sheet. Third, technical breakdown risk is high, with the stock just 4.6% above its 52-week low of $105.29; a decisive break below that level could trigger momentum-driven selling. Fourth, competitive and macro risks include exposure to industrial capex cycles and potential delays in utility infrastructure spending, which could pressure the Applied Water and Measurement & Control segments. Finally, valuation risk remains: the PEG ratio of 4.89 and the wide analyst target range of $129–$180 reflect high uncertainty about the growth trajectory.
Our 12-month forecast assigns a 55% probability to a base case where the stock trades in the $129–$154 range, reflecting steady execution with low-single-digit revenue growth and a gradual recovery toward the analyst average target of $153.88. The bull case (25% probability) targets $154–$180, driven by a reacceleration in revenue growth above 5%, margin expansion, and a re-rating to a 20–22x forward PE. The bear case (20% probability) targets $95–$105, assuming revenue growth stalls below 2%, margins compress, and the stock breaks below its 52-week low of $105.29. The most likely scenario is the base case, which assumes revenue growth stabilizes in the 2–4% range and free cash flow recovers to $800 million–$1 billion on a trailing basis. The key assumption behind this forecast is that the current revenue deceleration is a temporary pause rather than the start of a durable downturn.
XYL appears undervalued on forward metrics but fairly valued to slightly expensive on trailing metrics. The forward PE of 17.22x is well below the trailing PE of 34.65x, implying the market expects earnings to roughly double to $7.78 per share. The PB ratio of 2.89x is near the low end of its five-year historical range of 2.64x–7.21x, and the PS ratio of 3.67x is below historical peaks. However, the PEG ratio of 4.89 is elevated, indicating the stock is not cheap relative to its growth rate. The market is pricing in a successful earnings recovery that has yet to materialize; if forward estimates are met, the stock is undervalued, but if they are revised down, the valuation could prove expensive. Relative to the broader industrial machinery sector, XYL's forward PE is in line, but its historical premium has compressed significantly.
From a risk/reward perspective, XYL offers a compelling but uncertain proposition. The average analyst target of $153.88 implies 43.1% upside from $107.56, and the forward PE of 17.22x is reasonable for a company with stable gross margins and a fortress balance sheet (debt-to-equity of 0.18). However, the stock is down 24.35% over one year, revenue growth has decelerated to 2.71%, and Q1 free cash flow was only $18 million, suggesting the market is pricing in real risks. For value-oriented investors with a 12–18 month horizon, the stock could be a good buy if revenue growth stabilizes and cash flow normalizes; for momentum or short-term traders, the negative relative strength (-39.36% vs. SPY) and proximity to the 52-week low make it a risky entry. A prudent approach would be to wait for a confirmed technical base above $105 and evidence of reaccelerating growth before committing capital.
XYL is better suited for long-term investment than short-term trading. The company operates in a stable, essential industry (water technology) with a strong balance sheet (debt-to-equity of 0.18) and a dividend yield of 1.18%, but its near-term growth is modest (2.71% revenue growth) and its beta of 1.0 offers no volatility advantage. The stock is in a confirmed downtrend, down 24.35% over one year with negative relative strength, making short-term trading risky without a clear catalyst. For long-term investors, the forward PE of 17.22x and the 43.1% upside to analyst targets provide an attractive entry point if the earnings recovery materializes. A minimum holding period of 12–18 months is recommended to allow for a potential re-rating as revenue growth stabilizes and cash flow normalizes. Short-term traders should wait for a technical base above $105 and improving relative strength before considering entry.
